9/25/2019 | DD | Aegerion wraps up plan-based sale of equity interests to Amryt Pharma
|
9/11/2019 | DD | Aegerion Pharmaceuticals plan of reorganization confirmed by court
|
8/23/2019 | DD | Aegerion Pharmaceuticals plan OK’d by majority of voting creditors
|
7/11/2019 | DD | Aegerion Pharmaceuticals disclosure approved; plan hearing Sept. 5
|
7/1/2019 | DD | Aegerion loan, shared services agreement and investor protections OK’d
|
6/24/2019 | DD | Aegerion loan disposal dispute draws petition from Whitefort Capital
|
5/22/2019 | BKCVDD | Aegerion Pharmaceuticals files bankruptcy; plans sale to Amryt Pharma
|
3/4/2019 | CV | Market Commentary: Pluralsight offering on tap; Fortive convertibles dominate secondary; Guidewire expands
|
3/4/2019 | CV | Market Commentary: Morning Commentary: Fortive convertibles continue to dominate; Aegerion yield tops 91%
|
11/29/2016 | CV | Aegerion 2% convertibles now convertible for Novelion stock
|
6/16/2016 | CV | Aegerion 2% convertibles to be convertible into QLT shares post-merger
|
6/15/2016 | CV | Market Commentary: New ImmunoGen bond ends flat on debut; Dynegy launches $400 million of units; Par Pacific on tap
|
11/10/2015 | PP | Market Commentary: SunEdison, Aegerion contract sharply on hedge; new Aceto looks cheap, up in gray market
|
11/10/2015 | CV | Market Commentary: SunEdison, Aegerion contract sharply on hedge; new Aceto looks cheap, up in gray market
|
5/5/2015 | PP | Market Commentary: LinkedIn slips on hedge; Aegerion down; Cobalt adds; Anthem to price $900 million deal
|
5/5/2015 | CV | Market Commentary: LinkedIn slips on hedge; Aegerion down; Cobalt adds; Anthem to price $900 million deal
|
1/20/2015 | PP | Market Commentary: FXCM slips following details of Leucadia financing; SunEdison launches $350 million deal
|
1/20/2015 | CV | Market Commentary: FXCM slips following details of Leucadia financing; SunEdison launches $350 million deal
|
12/31/2014 | CV | Market Commentary: Outlook 2015: U.S. convertibles primary notches multi-year high; volume expected to climb
|
11/6/2014 | DD | Market Commentary: Molycorp bonds mauled on poor earnings; Cliffs also clobbered; hard-hit Aegerion comes back
|
11/6/2014 | HY | Market Commentary: Molycorp bonds mauled on poor earnings; Cliffs clobbered too; hard-hit Aegerion comes back
|
11/6/2014 | PP | Market Commentary: LinkedIn gains after pricing at cheap end; Aegerion regains ground; Salix shares plunge
|
11/6/2014 | CV | Market Commentary: LinkedIn gains after pricing at cheap end; Aegerion regains ground; Salix shares plunge
|
10/31/2014 | PP | Market Commentary: New Euronet adds outright, expands on swap; Aegerion drops after disappointing guidance
|
10/31/2014 | CV | Market Commentary: New Euronet adds outright, expands on swap; Aegerion drops after disappointing guidance
|
10/31/2014 | CV | Market Commentary: Morning Commentary: Euronet Worldwide adds outright; Aegerion drops after disappointing guidance
|
8/28/2014 | CV | Market Commentary: Morning Commentary: Newmont Mining weaker in trade; Aegerion shares retracing gains; trading quiet
|
8/27/2014 | PP | Market Commentary: Aegerion adds on swap with higher shares; Titan Machinery slips on swap on lower shares
|
8/27/2014 | CV | Market Commentary: Aegerion adds on swap with higher shares; Titan Machinery slips on swap on lower shares
|
8/15/2014 | PP | Market Commentary: New Priceline slips outright, trades flat on hedge after reoffer; existing Priceline off
|
8/15/2014 | CV | Market Commentary: New Priceline slips outright, trades flat on hedge after reoffer; existing Priceline off
|
8/12/2014 | PP | Market Commentary: New Aegerion flat to better amid weak shares; Nuance bonds active after earnings, call
|
8/12/2014 | CV | Market Commentary: New Aegerion flat to better amid weak shares; Nuance bonds active after earnings, call
|
8/12/2014 | CV | Market Commentary: Morning Commentary: New Aegerion adds despite weaker shares; planned Ligand looks cheap
|
8/12/2014 | CV | New Issue: Aegerion Pharmaceuticals sells upsized $300 million five-year convertibles at 2%, up 35%
|
8/11/2014 | CV | Market Commentary: Tesla adds on upgrade; Chiquita edges up on takeover offer; Empire State down since issue
|
8/11/2014 | CV | Market Commentary: Morning Commentary: Priceline up slightly with shares; Aegerion selling $250 million convertibles
|
8/11/2014 | CV | Aegerion Pharmaceuticals offers $250 million five-year convertibles to yield 2%-2.5%, up 30%-35%
|
6/15/2012 | PP | Aegerion prices $50.15 million public offering of its stock at $14.75
|
6/13/2012 | PP | Aegerion Pharmaceuticals plans to price public offering of its shares
|
11/14/2011 | CVHYPF | Aegerion files $125 million shelf covering stock, preferreds and debt
|
6/24/2011 | PP | Aegerion Pharmaceuticals prices $65.88 million public stock offering
|
6/16/2011 | PP | Aegerion Pharmaceuticals to offer common stock through public offering
|
3/4/2011 | PV | Aegerion enters into up to $25 million loan agreement with Hercules
|
6/13/2006 | BT | Aegerion Pharmaceuticals completes $22.5 million series A round
|